Healio

XEN1101 significantly reduced monthly seizures for adults with focal-onset epilepsy

Please provide your email address to receive an email when new articles are posted on . XEN1101 is a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener. A 25 mg dose of XEN1101 ...
Yahoo Finance

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

LONDON, June 05, 2025--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study, evaluating comprehensive outcomes of ...
PharmiWeb

Angelini Pharma’s Cenobamate receives approval in Ireland for use in adults with focal onset seizures in adult patients with epilepsy

Angelini Pharma’s Cenobamate receives approval in Ireland for use in adults with focal onset seizures in adult patients with epilepsy London, UK, May 15 2023 – Angelini Pharma has today announced that ...
PharmiWeb

Cenobamate (ONTOZRY®), for the Treatment of Uncontrolled Focal-onset Seizures in Adults, Is Now Available in France and Belgium

PARIS--(BUSINESS WIRE)--Angelini Pharma, international pharmaceutical company part of the privately held Italian Angelini Group, today announced that ONTOZRY® (cenobamate) is now available in France ...
Healio

Xcopri provides long-term seizure control in patients with focal epilepsy

Please provide your email address to receive an email when new articles are posted on . Long-term use of Xcopri was safe and reduced seizures by more than 90% in adults with uncontrolled focal ...
News Medical

A novel drug reduces the monthly frequency of seizure in adults with focal epilepsy

Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...
Yahoo Finance

Results of a Randomised Study Showing that Adjunctive Cenobamate Significantly Improved Seizure control in Adults with Uncontrolled Focal Seizures Published in Neurology(1)

ZUG, Switzerland, May 21, 2020 (GLOBE NEWSWIRE) -- Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today ...
Reuters

Marinus tanks as adult focal onset seizure drug fails late stage

(Reuters) - Marinus Pharmaceuticals Inc said it plans to stop development of its treatment for drug-resistant focal onset seizures in adults after it failed a late-stage trial, sending the company's ...
Medscape

for Focal Epilepsy

The US Food and Drug Administration (FDA) has approved cenobamate (Xcopri, SK Life Science) for the treatment of partial-onset seizures in adult patients with epilepsy. Today's approval was based on ...
Kauppalehti

Arvelle Therapeutics: SK Life Science, Inc. Announces US Availability of XCOPRI® (cenobamate tablets) for the Treatment of Partial (Focal) Onset Seizures in Adults with Epilepsy

Zug, Switzerland, 12 May 2020 -Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today confirms that SK ...
Science Daily

UV LED therapy shows promising results in preventing focal seizures

Researchers have discovered that light from an ultraviolet diode (UV LED) reduced "seizure-like" activity in a rat epilepsy model. Results of this study have considerable potential in treating focal ...
Seeking Alpha

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures “It is critically important to conduct long-term, real-world studies like CORE ...